<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02097394</url>
  </required_header>
  <id_info>
    <org_study_id>RJYYXHNK-002</org_study_id>
    <nct_id>NCT02097394</nct_id>
  </id_info>
  <brief_title>The Clinical Study on Combizym and Bifidobacteri to Prevent the Recurrence of Colon Polyps</brief_title>
  <official_title>A Randomized Controlled Study on Combizym and Bifidobacteria to Prevent the Recurrence of Colon Polyps</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is whether digestion enzyme(Combizym) and intestinal flora
      drugs(Bifidobacteria) can decease recurrence rate of colon polyps
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colon polyps has high recurrence rate in the digestion diseases. However, the reasons are not
      clear. The possible reasons for the recurrence of colon polyps include intestinal
      inflammation (e.g., Ulcerative colitis), intestinal flora imbalance (the benefit intestinal
      bacteria reduced, which lead to diarrhea or constipation), long-term indigestion. The
      investigators propose to examine whether digestion enzyme (Combizym) and intestinal flora
      drugs(Bifidobacteria) can decease recurrence rate of colon polyps
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrence of colon polyps</measure>
    <time_frame>one year</time_frame>
    <description>The whole patients need be examined by colonoscopy one year later. The recurrence rate of colon polyps will be acquired in different arms</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Combizym</condition>
  <condition>Bifidobacteri</condition>
  <condition>Colon Polyps</condition>
  <arm_group>
    <arm_group_label>Combizym</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These patients who have cutted colon polyps will eat the digestion enzyme(Combizym) regularly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bifidobacteri</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These patients who have cutted colon polyps will eat Bifidobacteri regularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combizym + Bifidobacteri</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These patients who have cutted colon polyps will eat drugs (Combizym + Bifidobacteri) regularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>these patients who have cutted colon polyps will not eat any drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combizym</intervention_name>
    <description>Combizym( 1 tablet, po, tid)</description>
    <arm_group_label>Combizym</arm_group_label>
    <other_name>Oryz-Aspergillus Enzyme And Pancreatin Tablet</other_name>
    <other_name>(produced by Nordmark Arzneimittel GmbH &amp; Co. KG)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bifidobacteri</intervention_name>
    <description>Bifidobacteri (2 tablet, po, tid)</description>
    <arm_group_label>Bifidobacteri</arm_group_label>
    <other_name>Live Combined Bifidobacterium，Lactobac and Enterococcus Capsules</other_name>
    <other_name>(produced by Shanghai XinYi Company)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combizym + Bifidobacteri</intervention_name>
    <description>Combizym( 1 tablet, po, tid) + Bifidobacteri (2 tablet, po, tid)</description>
    <arm_group_label>Combizym + Bifidobacteri</arm_group_label>
    <other_name>Combizym(Oryz-Aspergillus Enzyme And Pancreatin Tablet)</other_name>
    <other_name>(produced by Nordmark Arzneimittel GmbH &amp; Co. KG)</other_name>
    <other_name>Bifidobacteri(Live Combined Bifidobacterium，Lactobac and Enterococcus Capsules)</other_name>
    <other_name>(produced by Shanghai XinYi Company)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control</intervention_name>
    <description>have no any drug</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Patients who have cutted colon polyps in one month, and the diagnosis were proved by
        pathological analysis

        Exclusion Criteria:

          -  have organic or other functional disease

          -  pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengliang Chen</last_name>
    <role>Study Director</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2013</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2014</study_first_posted>
  <last_update_submitted>April 23, 2017</last_update_submitted>
  <last_update_submitted_qc>April 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Shengliang Chen</investigator_full_name>
    <investigator_title>professor,chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Polyps</mesh_term>
    <mesh_term>Colonic Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatin</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

